Deciphera Pharmaceuticals

Deciphera is honored to have received the #GreatPlaceToWork certification! This is the third year that our U.S. offices have received this award, the second year in Switzerland, and the first in Germany! This certification is a testament to the dedication and hard work of our incredible team. We are so grateful to the talented members at Deciphera helping us to improve the lives of patients. Learn more about this achievement: https://bit.ly/4j45ZiS

We are very excited to share that Deciphera Switzerland received first place in the micro category of Best Workplaces™ Switzerland 2025! The team attended the Best Place to Work award ceremony last week to celebrate this prestigious distinction. This award underscores our team’s outstanding corporate culture, passion and dedication to bringing transformational medicines to patients. The award reaffirms what we live every day: At Deciphera we foster a work culture based on a foundational set of values, Patients, Accountability, Transparency, Honesty and Integrity, and Stewardship. We strive every day to make The Deciphera Difference. Learn more about what makes us a special place to work: https://lnkd.in/eVxsxaq7 #BestWorkplaces2025 #GreatPlaceToWork #WorkplaceCulture

Deciphera is honored to have received the #GreatPlaceToWork certification! This is the third year that our U.S. offices have received this award, the second year in Switzerland, and the first in Germany! This certification is a testament to the dedication and hard work of our incredible team. We are so grateful to the talented members at Deciphera helping us to improve the lives of patients. Learn more about this achievement: https://bit.ly/4j45ZiS

Today, ONO PHARMACEUTICAL CO., LTD., the parent company of Deciphera, announced its financial results for the fourth quarter and fiscal year 2024. Read more: https://bit.ly/42O4uAx

We’re in Padova, Italy for EMSOS 2025, the European Musculo-Skeletal Oncology Society annual meeting! Our team will be sharing an oral presentation and two e-posters on Vimseltinib. Learn more about this conference: https://bit.ly/42OvVch #TGCT #EMSOS2025

April 7th marks the founding of the World Health Organization as well as #WorldHealthDay. We're proud to support this initiative drawing attention to health topics impacting those all over the world and remain steadfast in our commitment to bring transformational medicines to patients in need. Learn more about World Health Day: https://lnkd.in/eA53q7BF

Last week, our team attended the ESMO - European Society for Medical Oncology Sarcoma and Rare Cancers Annual Congress in Lugano, Switzerland. We were happy to connect with health care professionals and industry professionals in #oncology and #rarediseases at this prestigious conference to discuss ways to bring transformational medicines to patients.

We want to recognize our dedicated team, some of whom are pictured here with Deciphera CEO, Ryota Udagawa, as they were instrumental in last month’s FDA approval of a new medicine for people living with tenosynovial giant cell tumor (#TGCT). Thank you, team! Learn more about our recently approved medicine: https://bit.ly/4b8uDwn

Last week, Deciphera’s Management team had an incredible trip to Japan, visiting our parent company ONO PHARMACEUTICAL CO., LTD. at its headquarters in Osaka. Thank you to our hosts for the collaborative and productive week. We enjoyed our time together!

Today, on Rare Disease Day, we’re highlighting tenosynovial giant cell tumor (#TGCT), a rare, locally aggressive neoplasm that can negatively impact quality of life for those affected. Learn more: https://lnkd.in/g-_SCzFn #RareDiseaseDay Rare Disease Day